Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand the study and are willing to sign a consent form voluntarily
• People aged 18 or older, of any gender
• People who have been diagnosed with liver cancer (hepatocellular carcinoma), confirmed either by tissue testing or through clinical assessment
• People whose liver cancer did not respond to, or who could not tolerate, a first-line treatment combining a PD-1/PD-L1 immunotherapy drug with bevacizumab
• People with a general health and activity level rated 0, 1, or 2 on a standard medical scale (meaning able to carry out at least some daily activities)
• People with a certain level of liver function, rated as Child-Pugh class A or class B with a score of 7 or lower, and no history of a condition where the liver cannot remove toxins from the blood (hepatic encephalopathy)
• People with a life expectancy of at least 3 months
• People who have at least one measurable area of cancer visible on scan, as assessed by standard imaging guidelines
• People with adequately functioning organs and bone marrow, confirmed by tests done within 7 days before starting the study treatment
• People with an active hepatitis B or C infection must be receiving ongoing antiviral treatment
• People who are capable of having children must use highly effective contraception with their partner during treatment and for at least 180 days after the last dose

Who may not be able to join:

• People who are unable or unwilling to follow the study procedures
• People whose liver cancer has been identified by tissue testing as a specific rare type, including fibrolamellar HCC, sarcomatoid HCC, cholangiocarcinoma, or mixed hepatocellular-cholangiocarcinoma
• People who have previously had a liver transplant or are planning to have one
• People whose cancer has spread to the brain or the lining around the brain or spinal cord
• People whose scans show a severe form of cancer blocking the main portal vein (Vp4 portal vein tumour thrombosis)
• People with a known allergy or sensitivity to any of the study drugs or their ingredients, or a history of severe allergic reactions
• People who have both hepatitis B and hepatitis C infections at the same time
• People with significant fluid build-up in the abdomen that required medical treatment during the screening period
• People currently taking another experimental drug or who have participated in another clinical trial within 4 weeks before joining
• People who have had bleeding from veins in the oesophagus or stomach due to liver-related pressure problems within the past 6 months, or who have been found to have high-risk veins on a camera examination within the past 3 months
• People with an active or previous lung condition involving inflammation or scarring of the lung tissue (such as interstitial lung disease or pulmonary fibrosis) that could make it difficult to assess immune-related lung side effects
• People with poorly controlled high blood pressure (readings of 160/100 mmHg or above despite medication), or significant heart conditions including coronary artery disease, irregular heart rhythm, or heart failure
• People with a serious ongoing infection that requires antibiotic or antifungal treatment given through a drip
• People with significant levels of protein detected in their urine (2+ or above, or 1.0g or more in 24 hours)
• People who have had a significant bleeding episode of any severity within the 2 months before joining
• People who have had a blood clot in an artery or vein, or a stroke or mini-stroke (TIA), within the past 12 months
• People who have had a heart attack, acute coronary event, or heart bypass surgery within the past 6 months
• People with wounds or fractures that have not fully healed
• People with blood clotting disorders or who are currently taking blood-thinning medication
• People who have had another cancer within the past 5 years, with the exception of certain fully treated skin cancers or early-stage cervical cancer
• People with an active autoimmune disease, or a history of autoimmune disease that required immune-suppressing treatment within 4 weeks before joining
• People who have previously received a bone marrow transplant from a donor, or a transplanted organ from another person
• People whom the trial doctor considers unsuitable for medical or safety reasons (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.